Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott, BMS Suffer Blows On Antiretrovirals Kaletra and Reyataz As Indian Patent Office Rejects Patent Claims

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's Deputy Controller of Patents and Designs from the Mumbai branch of the Indian Patent Office rejected Dec. 30 Abbott's patent request for its popular second-generation antiretroviral Kaletra (lopinavir/ritonavir). Abbott had applied for a patent of a heat stable formulation of Kaletra nearly three years ago

You may also be interested in...



Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 2 of 2)

Gilles Picard discusses how to reach patients across a mix of developed and frontier markets in his role as VP of Asia, Australia, Africa and the Middle East for AbbVie, the innovative biopharma company split from parent Abbott Laboratories at the start of the year.

Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions

As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma

Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions

As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel